Achilles Therapeutics plc (NASDAQ:ACHL) Sees Significant Increase in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 122,300 shares, a growth of 35.4% from the December 31st total of 90,300 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average daily volume of 169,400 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Investors Weigh In On Achilles Therapeutics

An institutional investor recently raised its position in Achilles Therapeutics stock. XTX Topco Ltd increased its stake in Achilles Therapeutics plc (NASDAQ:ACHL) by 239.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,660 shares of the company’s stock after buying an additional 36,441 shares during the quarter. XTX Topco Ltd owned approximately 0.13% of Achilles Therapeutics worth $42,000 as of its most recent SEC filing. Institutional investors and hedge funds own 56.38% of the company’s stock.

Achilles Therapeutics Stock Down 0.9 %

NASDAQ:ACHL opened at $1.12 on Friday. Achilles Therapeutics has a twelve month low of $0.63 and a twelve month high of $1.76. The business has a 50 day moving average price of $1.10 and a two-hundred day moving average price of $0.96. The company has a market cap of $46.03 million, a P/E ratio of -0.68 and a beta of 1.32.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.